BioCanCell, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer, appointed Ronald Knickerbocker, Ph.D., as senior vice president of Clinical Development and Data Sciences, and Sean Daly as vice president of Clinical Operations.

Dr. Knickerbocker joins BioCanCell from ARIAD Pharmaceuticals, where he was vice president, Biomedical Data Sciences and Information and led the Biostatistics and Data Management functions through multiple successful oncology submissions.

Sean Daly also joins BioCanCell from ARIAD Pharmaceuticals, where he most recently served as the vice president of Clinical Operations. Sean led the clinical operations group at ARIAD for five years, building upon various operational roles held at ARIAD since 2004. 

“We are pleased to welcome Ron and Sean, both accomplished biotechnology executives to our management team,” said Frank Haluska, M.D, Ph.D., president and chief executive officer of BioCanCell. “Ron led protocol design, data analysis, and regulatory data submission for two globally-marketed cancer agents, and Sean implemented and executed the successful world-wide clinical trial program on which the drug submissions were based. They are important additions to BioCanCell at this time, as we advance our lead candidate, BC-819, a first-in-class potential therapy in late-stage development for non-muscle-invasive bladder cancer.”